ERBB2 and complete blood cell count: The univariate analysis of OS according to tumor subtype showed significant differences between MBC and FBC; lower survival was observed in males than females with the TN (2-year OS: 77.4%, p < 0.01), HoR-positive/HER2-positive (2-year OS: 85.8%, p < 0.01) and HoR-positive/HER2-negative subtypes (2-year OS: 93.8%, p < 0.01).